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PTreatment With Ezetimibe Plus Low-Dose
Atorvastatin Compared With Higher-Dose Atorvastatin Alone
Is Sufficient Cholesterol-Lowering Enough to Inhibit Platelets?
Michael Piorkowski, MD,* Sabine Fischer, MD,* Caroline Stellbaum, MD,* Markus Jaster, MD,*
Peter Martus, PHD,† Andreas J. Morguet, MD,* Heinz-Peter Schultheiss, MD,* Ursula Rauch, MD*
Berlin, Germany
Objectives We sought to test the platelet inhibitory and anti-inflammatory effects of a higher statin dosage compared with
combined treatment with ezetimibe plus a low statin dose.
Background Reducing the level of low-density lipoprotein cholesterol (LDL-C) with statins induces important pleiotropic ef-
fects such as platelet inhibition. An insufficient LDL-C reduction often is treated with ezetimibe, an intestinal cho-
lesterol absorption inhibitor, in combination with a low statin dose. It is not known whether this combination
therapy has the same pleiotropic effects as a statin monotherapy.
Methods Fifty-six patients with coronary artery disease were assigned randomly to receive either 40 mg/day of atorvasta-
tin or 10 mg/day of ezetimibe plus 10 mg/day of atorvastatin for 4 weeks. The levels of LDL-C, platelet activa-
tion markers after stimulation, platelet aggregation, and plasma chemokine levels (i.e., regulated on activation
normally T-cell expressed and secreted [RANTES]) were measured before and after changing lipid-lowering
medication.
Results Platelet activation markers (P-selectin) after stimulation (adenosine diphosphate) were reduced by 40 mg/day
of atorvastatin (5.2  1.6 arbitrary units) but not by ezetimibe plus low-dose atorvastatin (2.1  1.8 arbitrary
units; p  0.005) despite a similar reduction of LDL-C (atorvastatin 1.01  0.18 mmol/l vs. ezetimibe plus
atorvastatin 1.36  0.22 mmol/l, p  NS). Thrombin receptor-activating peptide-induced platelet aggregation
as well as plasma RANTES levels were reduced by 40 mg/day of atorvastatin but not by ezetimibe plus low-dose
atorvastatin.
Conclusions Platelet reactivity and a proinflammatory chemokine were reduced more by the higher atorvastatin dose than by
ezetimibe plus low-dose atorvastatin. In patients with coronary artery disease, it might be important to combine
ezetimibe with higher statin dosages to benefit from cholesterol-independent pleiotropic effects. (J Am Coll
Cardiol 2007;49:1035–42) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.064c
(
p
r
P
s
l
m
c
r
m
t
t
sJournal Club 
Selection
www.jaccjc.org
The relationship between coronary artery dis-
ease (CAD) and elevated low-density lipopro-
tein cholesterol (LDL-C) levels is well estab-
lished (1,2). The lowering of LDL-C using
HMG-CoA reductase inhibitors (statins) has
been found to substantially reduce cardiovascu-
ar mortality (3). The reduced mortality is attributed not
nly to the lowering of LDL-C but also to the numerous
leiotropic effects of statins (3–6). The inhibition of plate-
ets by statins is well documented in patients with hyper-
rom the *Department of Internal Medicine/Cardiology and †Institute for Biosta-
istics and Clinical Epidemiology, Campus Benjamin Franklin, Charité Universitäts-
edizin Berlin, Berlin, Germany.t
Manuscript received April 19, 2006; revised manuscript received October 20, 2006,
ccepted October 23, 2006.holesterolemia and CAD as well as in healthy individuals
7–10).
Despite the established efficacy of statins, the number of
atients who achieve and maintain a LDL-C level as
ecommended by the U.S. National Cholesterol Education
rogram and the Joint Task Force of European Societies is
uboptimal (11–14). Titration to higher statin dosages is
imited because of increasing adverse side effects, such as
yopathy and hepatotoxicity (15,16).
Ezetimibe, an intestinal cholesterol absorption inhibitor,
an be used as an additional therapy if statin therapy fails to
educe a patient’s levels of LDL-C (17,18). The comple-
entary actions of statins and ezetimibe offer a potent
reatment option via dual inhibition of 2 sources of choles-
erol (19). Moreover, combining the 2 substances eliminates
ide effects such as statin-associated myopathy and hepato-
oxicity and ezetimibe-induced compensatory-elevated
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(18,20). Although the combina-
tion of ezetimibe with a low ator-
vastatin dosage provides a very
potent tool for reducing LDL-C,
it is not known whether the com-
bined treatment strategy achieves
the same platelet inhibitory and
anti-inflammatory effects as ther-
apy with higher atorvastatin dos-
ages (21–23). We therefore in-
vestigated patients with CAD to
determine whether combined
treatment with ezetimibe plus
low-dose atorvastatin had differ-
ent effects on platelet function
and plasma chemokine levels
than higher-dose therapy with
atorvastatin alone.
Methods
Study design. The study in-
cluded 56 patients with clini-
cally stable CAD and LDL-C
2.5 mmol/l despite ongoing atorvastatin therapy with
0 or 20 mg/day. The patients met the following inclu-
ion criteria: angiographically documented CAD, concur-
ent medication with aspirin and clopidogrel, and age
etween 18 and 80 years. Antiplatelet therapy with aspirin
nd clopidogrel had to be maintained throughout the entire
tudy period. Exclusion criteria were a history of myocardial
nfarction or creatine kinase elevation within the last 4
eeks, recent warfarin treatment, tumors, severe renal
nsufficiency, active liver disease or known liver cirrhosis,
nclarified transaminase increase, recent antibiotic therapy,
nd known alcohol abuse.
Patients were assigned randomly (28:28) to receive either
0 mg/day of atorvastatin (group A) or a combination of 10
g/day of atorvastatin plus 10 mg/day of ezetimibe (group
). The experimental regimen was initiated without a
ashout period. Before and 4 weeks after changing the
DL-C-lowering medication, blood was drawn for ex vivo
latelet stimulation, platelet aggregation, plasma chemokine
evels (i.e., regulated on activation normally T-cell expressed
nd secreted [RANTES]), and lipid levels (LDL-C, high-
ensity lipoprotein cholesterol [HDL-C], triglycerides
TG]). At the end of the study, 2 patients dropped out after
he general practitioner changed their lipid-lowering med-
cation, and 3 patients did not present again. Therefore, 51
atients (25:26) remained for statistical analysis.
The institutional review board of the hospital approved
he study protocol, and written informed consent was
btained from each subject. All procedures were performed
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
AU  arbitrary units
CAD  coronary artery
disease
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
MA  maximum
aggregation
MFI  median
immunofluorescence
intensity
RANTES  regulated on
activation normally T-cell
expressed and secreted
SL  maximum slope of
aggregation
TG  triglycerides
TRAP  thrombin receptor-
activating peptiden accordance with the Declaration of Helsinki. tx vivo platelet stimulation. Platelet reactivity during
DL-C lowering was evaluated by ex vivo platelet stimu-
ation with adenosine diphosphate (ADP) as previously
escribed (9). The protocol was tested in advance for
rtificial platelet activation (9). In brief, whole blood was
ollected in acidic citrate dextrose. Platelets were pelleted by
entrifugation. The resuspended platelets were stimulated
or 30 min with 20-mol/l ADP (Sigma Chemical Co., St.
ouis, Missouri), 10-mol/l of thrombin receptor-
ctivating peptide (TRAP; Calbiochem, San Diego, Cali-
ornia) or were left unstimulated. The density of P-selectin
nd CD 63 (lysosomal glycoprotein 53) was measured by
ow cytometry using monoclonal antibodies as previously
escribed (9,24,25). Data are given as the median immu-
ofluorescence intensity (MFI) in arbitrary units (AU) after
ubtraction of the unspecific mouse IgG binding.
latelet aggregation. Ex vivo platelet aggregation was
valuated by optical aggregometry in citrated plasma sam-
les at 37°C using the PAP 4 platelet aggregation pro-
ler (BIODATA Corporation, Horsham, Pennsylvania).
latelet-rich plasma was prepared from citrated whole blood
y centrifugation (1,315 g for 75 s). The final platelet count
as adjusted to 300 nl with autologous plasma. A total of 50
l of ADP (final concentration of 20 mol/l) or TRAP
final concentration of 10 mol/l) were added to induce
latelet aggregation. Platelet aggregation was measured and
ssessed in 38 of the 51 patients (n  17 in the atorvastatin
roup and n  21 in the ezetimibe plus atorvastatin group).
urves were characterized by the maximum aggregation
MA) in % and the maximum slope (SL) in %/s.
easurements of plasma chemokine levels. The plasma
ANTES levels were determined by an enzyme-linked
mmunoabsorbent assay (ELISA). The ELISA-developing
its were purchased from Bender MedSystems, and mea-
urements conforming to the manufacturer’s recommenda-
ions were performed with a VersaMax microplate ELISA
eader. Plasma RANTES levels were calculated using a
olynomial standard curve with SoftMax Pro 4.6 software
nd given in nanograms per milliliter.
tatistics. Data from all numeric variables were tested for
ormal distribution using the Kolmogoroff-Smirnov test.
hus, continuous data were presented as the mean  the
tandard error of the mean. The t test for dependent
amples was used to analyze the expressions of platelet
ctivation markers, platelet aggregation, plasma chemokine
evels, and plasma lipid levels before and after changing
reatment. Differences in platelet activation markers
MFI), platelet aggregation (MA, SL), plasma chemo-
ine levels (c), and plasma lipid levels (LDL-C,
HDL-C, TG) were calculated as the values after minus
efore changing treatment. MFI, MA, SL, c,
LDL-C, HDL-C, and TG were compared between
roups using the t test for independent samples. Demo-
raphic and clinical data were compared between groups
sing the t test for independent samples or the chi-square
est for nominal values. Values of p  0.05 (2-sided) were
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March 13, 2007:1035–42 Cholesterol Lowering and Platelet Inhibitiononsidered significant. All analyses were performed using
PSS for Windows, Release 11.0.1 (SPSS Institute, Chi-
ago, Illinois).
esults
oth groups of patients had a typical cardiovascular risk
rofile. They did not differ significantly with regard to age,
ender, body mass index, cardiovascular risk factors, cardiac
haracteristics and medication before changing lipid-
owering therapy (Tables 1 and 2). The study included
atients who had been receiving either 10 or 20 mg/day of
torvastatin. Ten of 25 patients in the atorvastatin group
nd 12 of 26 patients in the combination group (p  NS)
ad an intake of 10 mg/day of atorvastatin before changing
o study medication. With regard to the initial atorvastatin
ose, there were no differences in platelet inhibitory and
linical Characteristics andedication of the S udy Population
Table 1 Clinical Characteristics andMedication of the Study Population
Atorvastatin
(n  25)
Ezetimibe  Atorvastatin
(n  26)
Age (yrs) 61.4 1.8 62.0 2.1
Gender (male/female) 22/3 20/6
Weight (kg) 83.0 2.6 79.9 2.8
Height (cm) 174.6 1.9 171.4 1.6
Body mass index (kg/m2) 27.2 0.7 27.1 0.8
Ejection fraction (%) 69.5 2.1 62.4 4.2
Cardiovascular risk factors (n)
Hypercholesterolemia 25 26
Systemic hypertension 25 26
Diabetes mellitus 7 4
Adipositas 5 6
Tobacco use 16 18
Medication (n)
Aspirin and clopidogrel 25 26
Beta-blocker 24 19
Angiotensin-converting enzyme-
inhibitor/AT-1 blocker
22 18
Diuretics 12 15
Proton-pump inhibitor 15 15
Insulin/oral antidiabetics/diet 5/1/1 3/1/0
o differences were observed between the groups.
Alteration of Laboratory and Lipid Parameters by
Table 2 Alteration of Laboratory and Lipid P
Atorvastatin (n
Before
ASAT (IU/ml) 25.0 1.1
ALAT (IU/ml) 26.9 1.8
Creatine kinase (IU/ml) 103 9
Creatinine (mol/ml) 86.6 3.3
LDL-C (mmol/l) 3.49 0.18
HDL-C (mmol/l) 1.31 0.07
TG (mmol/l) 1.81 0.15
*p  0.05, †p  0.005, before versus after changing lipid-lowering m
ALAT alanine transaminase; ASAT aspartamine transaminase; HDL-C
cholesterol; TG  tryglyceride.ipid-lowering effects obtained by the study medication
data not shown).
hange in serum lipid levels. Low-density lipoprotein
holesterol levels were reduced in both groups 4 weeks after
hanging the lipid-lowering therapy (Table 2). The extent
f LDL-C reduction (LDL-C) did not differ significantly
etween the groups (atorvastatin, 1.01  0.18 mmol/l vs.
zetimibe plus atorvastatin, 1.36  0.22 mmol/l) (Fig. 1).
ccordingly, 16 of 25 (64%) patients in the atorvastatin
roup and 20 of 26 (77%) in the combination group
chieved the LDL-C treatment goal of 2.5 mmol/l (p 
S atorvastatin vs. ezetimibe plus atorvastatin). The
DL-C level did not change in either group during the
bservation period (Table 2). Reduced TG levels were
bserved in both the atorvastatin and the combination
roup (Table 2). The TG did not differ significantly
etween the groups (data not shown).
latelet reactivity after ex vivo platelet stimulation. Al-
hough the two treatment groups showed a similar LDL-C
eduction, they differed in their agonist-induced platelet
eactivity. The ADP-induced platelet P-selectin expression
Study Medication
eters by the Study Medication
Ezetimibe  Atorvastatin (n  26)
fter Before After
1.4 27.0 2.3 25.7 1.6
3.0 28.9 2.5 33.0 4.2
20 114 20 108 12
3.1 92.4 4.5 89.9 4.7
0.11† 3.61 0.22 2.25 0.16†
0.07 1.39 0.07 1.33 0.08
0.13† 1.71 0.17 1.35 0.11*
on.
Figure 1 Differences in Low-Density
Lipoprotein Cholesterol Levels (LDL-C)
Levels at 4 weeks after lipid-lowering therapy compared with levels before
changing treatment. Atorvastatin 40 mg/day (open bars, n  25) and
ezetimibe 10 mg/day plus atorvastatin 10 mg/day (solid bars, n  26).the
aram
 25)
A
25.3
30.0
137
83.8
2.48
1.27
1.47
edicati
high-density lipoprotein cholesterol; LDL-C low-density lipoprotein
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Cholesterol Lowering and Platelet Inhibition March 13, 2007:1035–42as reduced 4 weeks after atorvastatin treatment with 40
g/day (from 18.2 1.7 AU to 12.9 1.0 AU; p 0.005)
Fig. 2A). In addition, TRAP-induced P-selectin exposure
lso was diminished 4 weeks after higher-dose atorvastatin
reatment (from 29.2  2.1 AU to 23.0  2.0 AU; p 
.01) (Fig. 3A). The administration of ezetimibe plus
ow-dose atorvastatin for 4 weeks did not reduce P-selectin
xpression after stimulation with ADP (16.4  1.4 AU vs.
8.5  2.0 AU; p  NS) (Fig. 2A) or TRAP (32.1  2.8
U vs. 31.8  3.1 AU; p  NS) (Fig. 3A). Furthermore, a
ignificant difference in MFI was found between the 2
reatment groups. Higher-dose atorvastatin led to a larger
eduction of ADP-induced P-selectin expression than
zetimibe combined with low-dose atorvastatin (MFI
5.2 1.6 AU vs. 2.1 1.8 AU; atorvastatin vs. ezetimibe
Figure 2 Differences in ADP-Induced P-Selectin Expression on P
(A) Platelet P-selectin expression after adenosine diphosphate (ADP) stimulation a
25) or a combination of ezetimibe plus atorvastatin (solid bars, n  26). (B) Diffe
after 4 weeks of lipid-lowering therapy minus level before changing treatment). AU
Figure 3 Differences in TRAP-Induced P-Selectin Expression on
(A) Platelet P-selectin expression after stimulation with thrombin receptor-activatin
tin (open bars, n  25) or a combination of ezetimibe plus atorvastatin (solid bars
expression (level after 4 weeks of lipid-lowering therapy minus level before changinlus atorvastatin; p  0.005; Fig. 2B). The 2 study groups
howed no significant differences in MFI after stimulation
ith TRAP(6.2  2.2 AU vs. 0.2  3.1 AU; atorva-
tatin vs. ezetimibe plus atorvastatin; p  0.1) (Fig. 3B).
Comparable results were obtained when analyzing CD 63
xpression on the surface of stimulated platelets. High-dose
tatin therapy reduced CD 63 exposure on platelets stimu-
ated with ADP and TRAP (Table 3). However, CD 63
xpression was not reduced on stimulated platelets after
ombination therapy with ezetimibe plus statin (Table 3).
here was a significant difference in MFI between the 2
roups. Thus, therapy with 40 mg/day of atorvastatin
esulted in a larger reduction of CD 63 expression than
ombination treatment with ezetimibe plus 10 mg/day of
torvastatin (Table 3).
lets
line and after 4 weeks of lipid-lowering therapy with atorvastatin (open bars, n 
in median immunofluorescence intensity (MFI) in P-selectin expression (level
itrary units.
elets
ide (TRAP) at baseline and after 4 weeks of lipid-lowering therapy with atorvasta-
26). (B) Differences in median immunofluorescence intensity in P-selectin
tment). Abbreviations as in Figure 2.late
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March 13, 2007:1035–42 Cholesterol Lowering and Platelet Inhibitionlatelet aggregation. Platelet aggregation measurements
lso reflected the different effects of the lipid-lowering
edication in patients with CAD. We discovered that
DP-induced platelet aggregation was not altered by both
herapies (Tables 4 and 5). However, the TRAP-induced
aximum platelet aggregation, as well as the maximum
lope of the aggregation curves, was reduced by 40 mg/day
torvastatin but not by the combination of ezetimibe plus
ow-dose atorvastatin (Tables 4 and 5). Neither MA nor
SL differed significantly between the 2 study groups
Tables 4 and 5).
lasma chemokine levels. The plasma RANTES concen-
rations were reduced from 0.81  0.04 ng/ml to 0.70 
.05 ng/ml by higher-dose atorvastatin (p 0.05) (Fig. 4A)
ut were not significantly lowered by the combination of
zetimibe plus 10 mg/day of atorvastatin (0.81  0.04
g/ml vs. 0.75  0.04 ng/ml, before vs. after p  NS) (Fig.
A). No significant difference was found when comparing
ANTES c between the 2 groups (0.10  0.04 ng/ml
s. 0.06  0.04 ng/ml; atorvastatin vs. ezetimibe  ator-
astatin, p  NS) (Fig. 4B).
iscussion
n this study, three major findings were observed: 1) during
4-week treatment period, the degree of LDL-C reduction
chieved by 40 mg/day of atorvastatin was comparable with
hat obtained by 10 mg/day of ezetimibe in combination
ith 10 mg/day of atorvastatin; 2) platelet reactivity was
educed by lipid-lowering treatment with 40 mg/day of
torvastatin but not by combination therapy with ezetimibe
lus atorvastatin; and 3) the plasma RANTES concentra-
ion was reduced by 40 mg/day of atorvastatin but not by
zetimibe combined with 10 mg/day of atorvastatin.
hanges in serum lipid levels by lipid-lowering treat-
ent. The extent of LDL-C reduction and the number of
atients achieving the LDL-C goal of 2.5 mmol/l by the
zetimibe-atorvastatin combination in this study were com-
arable with data from previous studies evaluating the safety
nd tolerability of ezetimibe and atorvastatin coadministra-
ion (21,23). Although LDL-C did not differ significantly
latelet Surface CD 63 Expressionfter S im lation with ADP and TRAP
Table 3 Platelet Surface CD 63 ExpressionAfter Stimulation with ADP and TRAP
CD 63 Expression
(AU)
Atorvastatin
(n  25)
Ezetimibe  Atorvastatin
(n  26)
ADP TRAP ADP TRAP
MFI before changing
treatment
10.5 0.8 16.4 1.3 9.8 0.7 17.0 1.4
MFI after changing
treatment
7.8 0.4† 12.7 0.8* 10.3 0.7 18.8 1.8
MFI 2.8 0.9§ 3.6 1.4‡ 0.5 0.8 1.8 1.6
p  0.05, †p  0.005, before versus after changing lipid-lowering medication. ‡p  0.05, §p 
.01, atorvastatin versus ezetimibe  atorvastatin.
ADP  adenosine diphosphate; AU  arbitrary units; MFI  median immunofluorescence
ntensity; TRAP  thrombin receptor-activating peptide.etween the 2 groups, LDL-C tended to be more reduced
*y the combined treatment than by the 40 mg/day of
torvastatin. In a double-blind trial, Ballantyne et al. (21)
eported that 10 mg/day of ezetimibe combined with 10
g/day of atorvastatin had the same LDL-C reducing effect
s 80 mg/day of atorvastatin. This report indicates that the
ombination of ezetimibe plus low-dose atorvastatin is very
otent in reducing LDL-C levels. However, combining
zetimibe with higher statin dosages provided only small
dditional LDL-C reductions (21). Thus, higher-dose sta-
in therapy may not be necessary in combination with
zetimibe, considering the efficacy and safety of the low-
ose combinations (21).
latelet inhibition and anti-inflammatory effects. Inhi-
ition of platelets by statin therapy is a well-documented
ose-dependent effect (3–10). Cholesterol-dependent and
independent mechanisms may contribute to it. Impaired
latelet aggregation in vivo and in vitro was shown as a
esult of a decreased platelet stimulation by low-density
ipoproteins and their oxidation products, a cholesterol
epletion in the platelet plasma membrane, an impaired
ignal transduction because of a lack of intracellular isopre-
oids, a decreased thromboxane A2 synthesis, and an
mproved nitric oxide bioavailability (3–7,26,27). However,
t has not yet been clarified whether platelet inhibition by
tatin therapy depends on the reduction of LDL-C or on
he inhibition of intracellular signal pathways accompanied
y disaggregating effects. In the present study, ADP- and
RAP-induced platelet degranulation as well as TRAP-
nduced platelet aggregation was reduced by 40 mg/day of
torvastatin but not by ezetimibe plus low-dose atorvastatin
espite a comparable LDL-C reduction. The platelet in-
ibitory effects observed here were achieved by increasing
he atorvastatin dosage. A comparable reduction of the
DL-C level by ezetimibe plus low-dose atorvastatin did
ot result in similar platelet inhibitory effects. Therefore, we
ssume that the observed platelet inhibition by higher
torvastatin dose was mainly related to mechanisms inde-
endent of the LDL-C-lowering.
Despite the reduction of agonist-induced platelet degran-
lation and TRAP-induced platelet aggregation, 40 mg/day
f atorvastatin had no influence on ADP-induced platelet
ggregation. One explanation might be a previously de-
cribed minor effect of atorvastatin on ADP-induced plate-
aximum Platelet Aggregation (MA)fter ADP and TRAP Stimulation
Table 4 Maximum Platelet Aggregation (MA)After ADP and TRAP Stimulation
MA (%)
Atorvastatin
(n  17)
Ezetimibe  Atorvastatin
(n  21)
ADP TRAP ADP TRAP
MA before changing
treatment
31.7 3.3 26.6 2.8 37.0 4.1 30.5 4.1
MA after changing
treatment
31.0 3.5 18.7 3.3* 36.5 3.6 32.5 4.4
MA 0.7 3.2 7.9 3.2 0.5 3.7 2.0 4.9p  0.05, before versus after changing lipid-lowering medication.
MA  maximum aggregation; other abbreviations as in Table 3.
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Cholesterol Lowering and Platelet Inhibition March 13, 2007:1035–42et aggregation (28). A more important reason is the
oadministration of clopidogrel in our study. Because clo-
idogrel inhibits ADP-induced platelet aggregation, an
nfluence of atorvastatin is underestimated. This observation
s consistent with findings in several studies evaluating
ossible drug-drug interactions between atorvastatin and
lopidogrel (29–32).
The chemokine RANTES is produced by a variety of
eukocytes and platelets’ (33). It is expressed on the platelets’
urface after platelet -granule degranulation (34). It me-
iates platelet activation, platelet-leukocyte interaction, as
ell as attraction and homing of leukocytes (monocytes,
ymphocytes, natural killer cells, mast cells) at sites of
ascular injury and platelet deposition (33,34). It also is
hought to play a key role in the progression of atheroscle-
osis by promoting monocyte MCP-1 production, macro-
hage accumulation, and neointimal growth (34,35). Thus,
lasma RANTES not only serves as a marker of platelet
ctivation in vivo but also reflects inflammatory processes at
he arterial wall in atherosclerosis and hypercholesterolemia
33–38). In the present study, the plasma RANTES con-
entration was decreased by 40 mg/day of atorvastatin but
ot by ezetimibe plus low-dose atorvastatin despite the
imilar LDL-C reduction. Although the comparison of the
Figure 4 RANTES Levels in Blood Pre- and Post–Lipid-Lowering
(A) Plasma regulated on activation normally T-cell expressed and secreted (RA
atorvastatin (open bars, n  25) or a combination of ezetimibe plus atorvastat
after 4 weeks of lipid-lowering therapy minus level before changing treatment).
Maximal Slope of Aggregation After ADP and TR
Table 5 Maximal Slope of Aggregation After
SL (%/s)
Atorva
(n 
ADP
SL before changing treatment 0.85 0.05
SL after changing treatment 0.82 0.06
SL 0.04 0.05
*p  0.05, before versus after changing lipid-lowering medication.
SL  maximum slope of aggregation; other abbreviations as in Tabeduction in the RANTES concentration between the 2
roups showed no significant difference, it demonstrates
hat in vivo platelet activation and an inflammatory chemo-
ine tend to be more reduced by higher-dose atorvastatin
herapy. These results here are in agreement with findings
ndicating that the anti-inflammatory effects of atorvastatin
re independent of the degree of LDL-C reduction (6). In
ddition, pleiotropic effects for simvastatin but not for
zetimibe have been described by Landmesser et al. (39).
he authors demonstrated that, independent of their LDL-
-reducing capacity, simvastatin, but not ezetimibe, improved
ndothelial function in chronic heart failure patients.
Clinical trials have shown that a statin-associated reduc-
ion of CAD-related events correlates with the LDL-C
evel achieved (3,40). Recommended LDL-C levels of 1.8
mol/l (70 mg/dl) or 2.5 mmol/l (100 mg/dl) were only
btained by high-dose statin treatment. Thus, the dose-
ependent reduction of CAD-related events has been at-
ributed to the LDL-C–lowering properties of statins.
oreover, many of the pleiotropic effects of statins were
lso shown to be dose-dependent (6). We demonstrated
ere that atorvastatin has dose-dependent platelet inhibitory
ffects independent of its LDL-C–lowering capacity. Be-
ause platelet hyperreactivity is a strong predictor of cardio-
apy
concentration at baseline and after 4 weeks of lipid-lowering therapy with
lid bars, n  26). (B) Differences (c) in plasma RANTES concentration (level
oncentration.
timulation
and TRAP Stimulation
Ezetimibe  Atorvastatin
(n  21)
TRAP ADP TRAP
0.72 0.05 0.84 0.05 0.72 0.06
0.55 0.06* 0.88 0.05 0.73 0.07
0.17 0.06 0.04 0.04 0.01 0.07Ther
NTES)
in (so
c  cAP S
ADP
statin
17)

v
s
a
p
f
H
a
n
b
a
s
m
d
fi
i
C
T
4
i
i
1
a
m
c
r
m
m
s
h
l
s
r
R
U
m
1
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
1041JACC Vol. 49, No. 10, 2007 Piorkowski et al.
March 13, 2007:1035–42 Cholesterol Lowering and Platelet Inhibitionascular events in patients with CAD, platelet inhibition by
tatins may well influence their clinical outcome (2).
In this study, we only tested platelet inhibitory effects of
torvastatin at 10 and 40 mg/day. Conclusions regarding the
latelet inhibitory effect of atorvastatin at dosages different
rom the study medication have to be drawn carefully.
owever, the existence of a threshold dose below which no
dditional pleiotropic effects are observed cannot be defi-
itely excluded.
It should be noted that the reduction of platelet reactivity
y higher-dose atorvastatin dose was observed under full
ntiplatelet therapy with aspirin and clopidogrel. This
upports results demonstrating platelet inhibition when 20
g/day of atorvastatin were coadministrated with clopi-
ogrel (9). These observations are in contrast with previous
ndings suggesting that atorvastatin dose-dependently lim-
ts clopidogrel efficacy (41).
onclusions
he present study provides evidence that the therapy with
0 mg/day of atorvastatin has beneficial cholesterol-
ndependent effects on platelets and plasma RANTES levels
n patients with CAD. The administration of ezetimibe plus
0 mg of atorvastatin did not have these effects, although it
chieved an excellent reduction of LDL-C. These findings
ight be relevant in patients with atherosclerotic cardiovas-
ular disease where LDL-C reduction cannot be sufficiently
educed under standard statin therapy. In these patients, it
ight not be sufficient to lower the LDL-C level to 2.5
mol/l by using a combination of ezetimibe plus low-dose
tatin. Considering the pleiotropic effects of statins, we
ypothesize that it might be better to adjust the lipid-
owering medication by combining ezetimibe with a higher
tatin dose. Further clinical and experimental studies are
equired to test this hypothesis.
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